Company intelligence / Profile preview
Actimed Therapeutics
Ascot, Berkshire, United Kingdomactimedtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Actimed Therapeutics is developing treatments for cachexia and muscle wasting conditions. Their lead product, S-pindolol benzoate (ACM-001.1), has generated promising proof of concept Phase 2a clinical data in cachexia patients. The company received IND approval from FDA for S-pindolol benzoate in August 2023 for cancer cachexia treatment. Their second asset, S-oxprenolol (ACM-002), is being developed for muscle wasting in ALS and received Orphan Drug Designation from the FDA in 2024.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Faraday Pharmaceuticals
Beyond the preview
Go deeper on Actimed Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actimed Therapeutics.